Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment

Elena Seminari(Policlinico San Matteo Fondazione), Antonella Castagna(Vita-Salute San Raffaele University), Fernanda Dorigatti(Vita-Salute San Raffaele University), Giorgia Gentilini(Vita-Salute San Raffaele University), Laura Galli(Vita-Salute San Raffaele University), Giulia Schira(Vita-Salute San Raffaele University), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Nicola Gianotti(Vita-Salute San Raffaele University), Adriano Lazzarin(Vita-Salute San Raffaele University), A De Bona, Armando Soldarini(Vita-Salute San Raffaele University)
Journal of Antimicrobial Chemotherapy
July 10, 2007
10.1093/jac/dkm282
Cited by 16

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
|PLoS Medicine|2013|362
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
|New England Journal of Medicine|2022|312